<DOC>
	<DOC>NCT00089661</DOC>
	<brief_summary>The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.</brief_summary>
	<brief_title>AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma of the breast Subjects with early stage disease who are estrogen receptor positive and who have completed their treatment pathway (surgery, chemotherapy, radiation, and/or hormone therapy) and are currently on or will initiate aromatase inhibitor therapy, and are expected to stay on aromatase inhibitor therapy for the duration of the 24month study All treatment pathway must be completed ≥ 4 weeks prior to study entry, and all acute toxic effect of any above therapy must be resolved to ≤ Grade 1 by National Cancer Institution (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Female &gt; 18 years of age ECOG Performance status 0 and 1 Lumbar spine, total hip or femoral neck BMD equivalent to a tscore classification of 1.0 to 2.5 Subject is willing and able to provide signed consent before any studyspecific procedure Other criteria also apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Bone loss associated with Aromatase Inhibitor therapy (AIT) for non-metastatic BC</keyword>
	<keyword>osteopenia</keyword>
	<keyword>Low bone density</keyword>
</DOC>